New classification of chronic GVHD: added clarity from the consensus diagnoses

被引:70
作者
Arora, M. [1 ,2 ]
Nagaraj, S. [2 ]
Witte, J. [2 ]
DeFor, T. E. [2 ]
MacMillan, M. [2 ]
Burns, L. J. [2 ]
Weisdorf, D. J. [2 ]
机构
[1] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Pediat, Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
关键词
CGVHD; classification; consensus guidelines; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; CHRONIC GRAFT; CELL TRANSPLANTATION; CRITERIA;
D O I
10.1038/bmt.2008.305
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The Diagnosis and Staging Working Group of the NIH Consensus Development Project on Criteria for Clinical Trials in chronic GVHD (CGVHD) recently proposed criteria for diagnosis and assessment of overall CGVHD severity. We retrospectively reviewed 54 consecutive patients diagnosed with CGVHD between January 2002 and December 2005 after sibling donor transplant to assess the applicability of the new criteria in prognosticating survival and transplant-related mortality (TRM). A total of 8 patients (15%) were reclassified as late onset/persistent or recurrent acute GVHD (late aGVHD), 15 (28%) had overlap syndrome and 31 (57%) had classic CGVHD. Three-year overall survival was worse in patients with late aGVHD (3-year probability 25% (95% CI 4-56%)) followed by overlap syndrome (3-year probability 87% (95% CI 56-96%)) and CGVHD (3-year probability 75% (95% CI 54-87%)); P = 0.001. Among patients with overlap syndrome and CGVHD, a trend towards worse survival was seen in patients with severe disease (3-year probability 57.3% (95% CI 21-82%)) as compared to mild + moderate disease (3-year probability 85.1% (95% CI 68-94)); P = 0.1. This analysis, undertaken in a contemporary cohort of related donor recipients, indicates that the consensus guidelines are applicable to this population of CGVHD patients.
引用
收藏
页码:149 / 153
页数:5
相关论文
共 16 条
[1]   Development of a prognostic model for grading chronic graft-versus-host disease [J].
Akpek, G ;
Zahurak, ML ;
Piantadosi, S ;
Margolis, J ;
Doherty, J ;
Davidson, R ;
Vogelsang, GB .
BLOOD, 2001, 97 (05) :1219-1226
[2]   Chronic graft-versus-host disease: A prospective cohort study [J].
Arora, M ;
Burns, LJ ;
Davies, SM ;
MacMillan, ML ;
Defor, TE ;
Miller, WJ ;
Weisdorf, DJ .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (01) :38-45
[3]   National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].
Filipovich, AH ;
Weisdorf, D ;
Pavletic, S ;
Socie, G ;
Wingard, JR ;
Lee, SJ ;
Martin, P ;
Chien, J ;
Przepiorka, D ;
Couriel, D ;
Cowen, EW ;
Dinndorf, P ;
Farrell, A ;
Hartzman, R ;
Henslee-Downey, J ;
Jacobsohn, D ;
McDonald, G ;
Mittleman, B ;
Rizzo, JD ;
Robinson, M ;
Schubert, M ;
Schultz, K ;
Shulman, H ;
Turner, M ;
Vogelsang, G ;
Flowers, MED .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956
[4]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[5]   Incidence and outcome of chronic graft-versus-host disease using national institutes of health consensus criteria [J].
Jagasia, Madan ;
Giglia, Jennifer ;
Chinratanalab, Wichai ;
Dixon, Sheri ;
Chen, Heidi ;
Frangoul, Haydar ;
Engelhardt, Brian ;
Goodman, Stacey ;
Greer, John ;
Kassim, Adetola ;
Morgan, David ;
Ruffner, Katherine ;
Schuening, Friedrich .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (10) :1207-1215
[6]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[7]  
Lin DY, 1997, STAT MED, V16, P901, DOI 10.1002/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO
[8]  
2-M
[9]   Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems [J].
MacMillan, ML ;
Weisdorf, DJ ;
Wagner, JE ;
DeFor, TE ;
Burns, LJ ;
Ramsay, NKC ;
Davies, SM ;
Blazar, BR .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (07) :387-394
[10]   Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation [J].
Mielcarek, M ;
Storb, R .
LEUKEMIA & LYMPHOMA, 2005, 46 (09) :1251-1260